Executive SummaryRecently finalized licensing agreement with Johns Hopkins gives the San Diego-based drug R&D firm the exclusive license to develop antisense therapeutics produced by Hopkins researchers Paul Ts'o and Paul Miller. The deal includes 10 patents and applications covering composition of matter and methods of use related to Matagen oligonucleotides.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.